Median OS was 13.3 months (95% CI, 11.9–16.4 months) with chemotherapy alone versus 16.6 months (95% CI, 13.7–19.0 months) with bevacizumab plus chemotherapy, which did not reach statistical significance, but 40% of patients receiving chemotherapy crossed over to single-agent bevacizumab on progression, compromising the OS data. 26 In the OCEANS trial, the addition of bevacizumab to carboplatin/gemcitabine in patients with relapsed platinum-sensitive ovarian cancer also improved PFS, with PFS of 12
1
—
—